CN103408573B - 硼酸衍生物及其制备方法和应用 - Google Patents
硼酸衍生物及其制备方法和应用 Download PDFInfo
- Publication number
- CN103408573B CN103408573B CN201310293713.7A CN201310293713A CN103408573B CN 103408573 B CN103408573 B CN 103408573B CN 201310293713 A CN201310293713 A CN 201310293713A CN 103408573 B CN103408573 B CN 103408573B
- Authority
- CN
- China
- Prior art keywords
- boric acid
- acid derivatives
- butyl
- methyl
- propyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical class OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- -1 acetylene compound Chemical class 0.000 claims abstract description 52
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 12
- ZOCHARZZJNPSEU-UHFFFAOYSA-N diboron Chemical compound B#B ZOCHARZZJNPSEU-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 8
- 239000003513 alkali Substances 0.000 claims abstract description 6
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims abstract description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 5
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 20
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 11
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 claims description 8
- 239000002243 precursor Substances 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- BMIBJCFFZPYJHF-UHFFFAOYSA-N 2-methoxy-5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound COC1=NC=C(C)C=C1B1OC(C)(C)C(C)(C)O1 BMIBJCFFZPYJHF-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 239000003586 protic polar solvent Substances 0.000 claims description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000001207 fluorophenyl group Chemical group 0.000 claims description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical group C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 claims description 3
- 238000005815 base catalysis Methods 0.000 claims description 2
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 2
- 235000015320 potassium carbonate Nutrition 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 2
- 239000004327 boric acid Substances 0.000 abstract description 9
- 238000010189 synthetic method Methods 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- 229910052799 carbon Inorganic materials 0.000 description 30
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 26
- 238000000034 method Methods 0.000 description 26
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- LDPIQRWHBLWKPR-UHFFFAOYSA-N aminoboronic acid Chemical class NB(O)O LDPIQRWHBLWKPR-UHFFFAOYSA-N 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 150000001345 alkine derivatives Chemical class 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 13
- 229910002027 silica gel Inorganic materials 0.000 description 13
- 239000002585 base Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 230000002779 inactivation Effects 0.000 description 11
- 238000004440 column chromatography Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 6
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 238000006555 catalytic reaction Methods 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000012188 paraffin wax Substances 0.000 description 5
- 125000001151 peptidyl group Chemical group 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- MOILFCKRQFQVFS-BDNRQGISSA-N (1r,3s,4r,5r)-4,6,6-trimethylbicyclo[3.1.1]heptane-3,4-diol Chemical compound C1[C@@H]2C(C)(C)[C@H]1C[C@H](O)[C@@]2(O)C MOILFCKRQFQVFS-BDNRQGISSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 4
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 125000003368 amide group Chemical group 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 4
- 244000080767 Areca catechu Species 0.000 description 3
- 235000006226 Areca catechu Nutrition 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 0 [*+]C1[N+]CCC1 Chemical compound [*+]C1[N+]CCC1 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- WGLLSSPDPJPLOR-UHFFFAOYSA-N 2,3-dimethylbut-2-ene Chemical group CC(C)=C(C)C WGLLSSPDPJPLOR-UHFFFAOYSA-N 0.000 description 2
- GWJSQKNYHPYZRN-UHFFFAOYSA-N 2-methylpropane-2-sulfonamide Chemical compound CC(C)(C)S(N)(=O)=O GWJSQKNYHPYZRN-UHFFFAOYSA-N 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- 241000134253 Lanka Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000007259 addition reaction Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000011914 asymmetric synthesis Methods 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- 150000001728 carbonyl compounds Chemical class 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 150000004696 coordination complex Chemical class 0.000 description 2
- 150000004699 copper complex Chemical class 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 235000015177 dried meat Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000002524 organometallic group Chemical group 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 230000000707 stereoselective effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- ZYZCALPXKGUGJI-DDVDASKDSA-M (e,3r,5s)-7-[3-(4-fluorophenyl)-2-phenyl-5-propan-2-ylimidazol-4-yl]-3,5-dihydroxyhept-6-enoate Chemical compound C=1C=C(F)C=CC=1N1C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C(C)C)N=C1C1=CC=CC=C1 ZYZCALPXKGUGJI-DDVDASKDSA-M 0.000 description 1
- VUYQBMXVCZBVHP-UHFFFAOYSA-N 1,1-difluoroethanol Chemical compound CC(O)(F)F VUYQBMXVCZBVHP-UHFFFAOYSA-N 0.000 description 1
- WYBQOWXCLDXZNR-UHFFFAOYSA-N 2-(1,3,2-benzodioxaborol-2-yl)-1,3,2-benzodioxaborole Chemical compound O1C2=CC=CC=C2OB1B1OC2=CC=CC=C2O1 WYBQOWXCLDXZNR-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 1
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229940124036 Hydrolase inhibitor Drugs 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 238000006219 Matteson homologation reaction Methods 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Natural products P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- 102000003827 Plasma Kallikrein Human genes 0.000 description 1
- 108090000113 Plasma Kallikrein Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102100038124 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- KJRCEJOSASVSRA-UHFFFAOYSA-N Propane-2-thiol Natural products CC(C)S KJRCEJOSASVSRA-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 238000006161 Suzuki-Miyaura coupling reaction Methods 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000004093 hydrolase inhibitor Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- FGFUBBNNYLNVLJ-UHFFFAOYSA-N indolone Natural products C1=CC=C2C(=O)C=NC2=C1 FGFUBBNNYLNVLJ-UHFFFAOYSA-N 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- ZJQKISPTWPQBSR-UHFFFAOYSA-N methanamine;toluene Chemical compound NC.CC1=CC=CC=C1 ZJQKISPTWPQBSR-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000007040 multi-step synthesis reaction Methods 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000013037 reversible inhibitor Substances 0.000 description 1
- XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical group OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 150000004756 silanes Chemical class 0.000 description 1
- 238000006884 silylation reaction Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- WZCZNEGTXVXAAS-UHFFFAOYSA-N trifluoromethanol Chemical compound OC(F)(F)F WZCZNEGTXVXAAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明属于有机化学领域，涉及硼酸的衍生物及其制备方法和应用，公开了具有通式（I）结构的硼酸衍生物，通过炔类化合物与二硼烷试剂，以氮杂卡宾配体和碱为催化剂合成。这种硼酸衍生物可用于制备治疗肿瘤或糖尿病的药物，也可以作为中间体制备其他药物。本发明合成方法可提高收率，降低药物制备成本，简化合成路线，具有较好的经济效益。
Description
技术领域
本发明属于有机化学领域，涉及硼酸的衍生物及其制备方法和应用。
背景技术
在自然界中，虽然不存在天然的氨基硼酸类化合物，但是其中的硼酸基团具有很特殊的天然氨基羧酸的伪饰性，从而让它具有引人入胜的生物活性，所述的与天然氨基酸特征类似的氨基硼酸类化合物为具有如下结构的化合物：
其中：R为天然氨基酸特征的各种取代基。
近年来氨基硼酸作为丝氨酸酶拮抗性的关键药效基团，在药物设计中越来越受到关注。由于硼原子独特的物理化学性质和空间结构（具有空的p轨道和较小的原子半径），□～氨基硼酸可以被设计成各种具有重要作用的水解酶抑制剂。如文献Shenvi,al.,US4499082(1985)Shenvi等揭示肽基氨基硼酸TM-1类化合物可以作为蛋白水解酶的抑制剂，文献Kentter,Shenvi,al.,US5187157(1993)，US5242904（1993），US5250720（1993）Kentter,Shenvi揭示肽基氨基硼酸TM-1类化合物同样可以作为胰岛素样丝氨酸水解酶的可逆性抑制剂，可作用于凝血酶，血浆激肽释放酶，血纤维蛋白溶酶，文献Kleeman,al.,US5169841(1992).Kleeman揭示N端连接肽基的氨基硼酸TM-2类化合物具有抑制肾素的活性，Kettner,al.,WO200102424(2001)Kettner等揭示肽基的氨基硼酸TM-3类化合物具有抑制C型肝炎病毒的作用，Kinder,al.,US5106948(1992)Kinder等报道了N端连接肽基的氨基硼酸TM-2类化合物具有抑制肿瘤细胞生长的作用，同样Bachovchin,al.,WO20070005991(2007)Bachovchin等揭示了肽基氨基硼酸TM-4类化合物具有抑制纤维原细胞活化蛋白(FPA)的作用，这预示着该类化合物具有抗肿瘤的活性，后期的相关研究表明具有抑制胰腺癌的潜质，Fleming;PaulE.al.,WO2011123502(2011)Fleming和PaulE.等揭示了含有环丙基的氨基硼酸TM-5类化合物具有抑制肿瘤细胞增长的作用，FDA近期批准了首例含□～氨基硼酸的骨髓瘤抑制剂Bortezomib，该新药已用于临床。另外，文献a)Snow,R.et.al.,J.Am.Chem.Soc.,1994,116,10860-10869.b)JackH.Lai,WilliamW.Bachovchin,et.al.,J.Med.Chem.2007,50,2391-2398.c)GeorgeR.Lankas,et.al.,Diabetes,2005,54,2988-2994.报导，肽基的脯氨基硼酸是二肽基脯氨基酶IV(DPP-4)的非常有效的抑制剂，可以作为II型糖尿病的很有前景的治疗药物，其中美国Phenomix公司的PT-100已完成FDA的III期临床。
文献：
Snow,R.et.al.,J.Am.Chem.Soc.,1994,116,10860-10869.：
JackH.Lai,WilliamW.Bachovchin,et.al.,J.Med.Chem.2007,50,2391-2398.
GeorgeR.Lankas,et.al.,Diabetes,2005,54,2988-2994.
K.Augustyns,P.VanderVeken,K.SentenandA.Haemers,CurrentMedicinalChemistry,2005,12,971-998.
PieterVanderVeken,AchielHaemersandKoenAugustyns,CurrentTopicsinMedicinalChemistry,2007,7,621-635.
DanielJDrucker,MichaelANauck,Lancet,2006;368:1696–705.
作为氨基硼酸乃至相应的光学纯对应异构体在化学合成方面研究，其实用性和多样性方面仍然有很大的挑战，特别是有效、简洁的立体选择性合成方面。以重要的丝氨酸水解酶抑制剂的关键中间体--脯氨基硼酸的合成为例，一般采用多步合成及拆分的方法，多以Pinanediol二硼烷酯和吡咯或四氢吡咯为起始原料，如文献E.ScottPriestley,CarlP.Decicco,US20030008828,(2003,1).的报导，第一条路线合成方法步骤长，收率低，第二条路线立体选择性不好，所用碱试剂对湿度敏感，操作性差，反应式如下所示：
目前有关氨基硼酸的不对称合成的方法很少，实际上只有二种方法被报道。一种是在学术和工业界被广泛使用的Mattheson的方法，如文献：DonaldS.MattesonandKizhakethilM.Sadhu,J.Am.Chem.SOC.1981,103,5241-5242.的报导，是利用含有手性辅基的Pinanediol二硼烷酯制备氯硼酸酯，然后进一步转化为氨基硼酸，该方法中，氨基硼酸的侧链都是由烷基硼酸衍生的，这大大限制了它们的商品化的可能，反应式如下：
Dupont制药公司的Kettner利用把侧链做成亲电试剂对Matteson的方法做了拓展，如文献SharadaJagannathan,TimothyP.Forsyth,andCharlesA.Kettner,J.Org.Chem.2001,66,6375-6380.的报导，尽管在一定程度上丰富了氨基硼酸的多样性，但就其所用的试剂和适用的范围仍具有很大的局限性。反应式如下：
上述制备氨基硼酸的方法都需经过多步的合成，如果直接通过一步直接构建目标化合物的方法最为理想，而有关硼对于碳杂双键的加成报道很少，文献GraceMann,KevinD.John,andR.TomBaker，Org.Lett.,2000,2(14),2105-2108.Baker等报道了一例N-芳基芳香醛亚胺在铂络合物催化下与Bis(catecholato)diboron(B2cat2)反应得到消旋的氨基硼酸酯，反应式如下：
在此基础上，直接的用手性叔丁基亚磺酰胺诱导的不对称合成方法，由Ellman发展成功，见文献MelissaA.Beenen,ChihuiAn,andJonathanA.Ellman,J.Am.Chem.Soc.2008,130,6910–6911的报导，该方法利用频哪醇二硼烷酯在(ICy)CuOtBu/叔丁醇钠的催化下与手性叔丁基亚磺酰亚胺反应得到手性□～氨基硼酸衍生物，尽管它具有高立体选择性和对脂肪链烷基取代亚胺底物收率较高的优点，然而就目前该方法仍然存在二个方面的问题，１）它使用了NHC的叔丁氧铜的卡宾铜络合物作为催化剂，该催化剂只能在特定的场所（如手套箱）中制备和存放，这限制了它的工业化运用前景；2）Ellman的方法在底物类型上存在局限性，通常对于烷基氨基硼酸的收率好(收率：74-88%)，而试验发现，芳基氨基硼酸的收率不好(收率：52-61%)，甚至得不到目标产物；
Ellman的方法的核心是使用含手性亚砜辅基的叔丁基亚磺酰胺底物对Cu(I)-氮杂卡宾催化的硼酯加成反应进行立体化学诱导。自从Wanzlick和Ofele在1968年首次报道了氮杂卡宾(NHC)与金属络合物以来，陆续已有许多稳定、可分离的该类化合物被报道，而该类化合物在催化有机金属反应时常常获得很好的效果，见文献a)Herrmann,W.A.Angew.Chem.Int.Ed.2002,41,1290-1309.b)Zinn,F.K.;Viciu,M.S.;Nolan,S.P.Annu.Rep.Prog.Chem.,Sect.B.2004,100,231-249.c)Scott,N.M.;Nolan,S.P.Eur.J.Inorg.Chem.2005,1815-1828的报导；
从给电子强度的角度来看，氮杂卡宾与富电性的膦化合物比较相似，是一类中性的2-电子给予体。可与多种过渡金属形成络合物，配位性质与富电子的有机膦配体相似，但二者立体化学性质又有明显的区别，见文献：a)Scholl,M.;Trnka,T.M.;Morgan,J.P.;Grubbs,R.H.TetrahedronLett.1999,40,2247-2250.b)Scholl,M.;Ding,S.;Lee,C.W.;Grubbs,R.H.Org.Lett.1999,1,953-956.c)Trnka,T.M.;Grubbs,R.H.Acc.Chem.Res.2001,34,18-29.d)Huang,J.K.;Stevens,E.D.;Nolan,S.P.;Petersen,J.L.J.Am.Chem.Soc.1999,121,2674-2678.e)Ackermann,L.;Furstner,A.;Weskamp,T.;Kohl,F.J.;Herrmann,W.A.TetrahedronLett.1999,40,4787-4790.的报导；
与金属的相互作用以σ-键为主，金属d轨道向卡宾的π反馈作用相对较弱,是一类典型的中性σ-配体，见文献：a)Bielawski,C.W.;Grubbs,R.H.Angew.Chem.Int.Ed.2000,39,2903-2906.b)Bielawski,C.W.;Benitez,D.;Grubbs,R.H.Science,2002,297,2041-2044.的报导；
利用氮杂卡宾(NHC)金属络合物催化的反应都被成功地运用到Heck,Suzuki-Miyaura,Kumada,Sonogashira,Still,Negishi,Buchwald-Harting反应中，见文献：
Herrmann,W.A.,Reisinger,C.P.,Siegler,M.,J.Organomet.Chem.1998,557,93-96.
Zhang,C.,Huang,J.,Trudell,M.L.,Nolan,S.P.,J.Org.Chem.,1999,64,3804-3805.
Grasa,G.A.,Nolan,S.P.,Org.Lett.,2001,3,119-122.
Huang,J.,Nolan,S.P.J.Am.Chem.Soc.,1999,121,9889-9890.b)Bohm,V.P.W.,Gstottmayr,C.W.K.,Weskamp,T.,Herrmann,W.A.,Angew.Chem.Int.Ed.2001,40,3387-3389.
Eckhardt,M.,Fu,G.C.,JAm.Chem.Soc.,2003,125,13642-13643.b)Aitenhoff,G.,Wuertz,S.,Glorius,F.TetrahedronLett.2006,47,2925-2928.
Grasa,G.A.,Nolan,S.P.,Org.Lett.,2001,3,119-122.
Hadei,N.,Kantchev,E.A.B.,Obrien,C.J.,Organ,M.G.,J.Org.Chem.,2005,70,8503-8507.
J.Huang,G.Grasa,S.P.Nolan,Org.Lett.,1999,1,1307-1309.b)Stauffer,S.R.,Lee,S.,Stambuli,J.P.,Hauck,S.I.,Hartwig,J.F.,Org.Lett.,2000,2,1423-1426.c)Marion,N.,Navarro,O.,Mei,J.,Stevens,E.D.,Scott,N.M.,Nolan,S.P.,J.Am.Chem.Soc.,2006,128,4101-4111
1993年，报道第一例Cu(I)-氮杂卡宾(NHC)络合物{[(NHC)2Cu][O3SCF3]}28，见文献：Arduengo,A.J.III.,Dias,H.V.R.,Calabrese,J.C.,Davidson,F.,Organometallics,1993,12,3405-3409.的报导；
文献：Jurkauskas,V.,Sadighi,J.P.,Buchwald,S.L.,Org.Lett.,2003,5,2417-2420.报导，Buchwald小组用铜(I)与现产生氮杂卡宾制备了单NHC铜(I)络合物，证明Cu(I)-氮杂卡宾(NHC)络合物是典型的二协同体，它随着氮上取代基与金属配合能力的增加，它的协同力也明显增加。并把它运用在不饱和羰基类化合物的碳碳双键的还原，文献：Kang-SangLee,Adil,R.ZhugralinandAmirH.Hoveyda,J.Am.Chem.Soc.,2009,131,7253-7255.报导，Hoveyda小组利用氮杂卡宾在无金属盐存在下来催化不饱和羰基类化合物和二硼酸酯反应，构建硼酸酯羰基化合物。
纵观氨基硼酸的构建方法、氮杂卡宾本身及其铜络合物在催化二硼烷试剂对碳杂双键加成反应中的运用，其他研究小组到目前为止，从反应的机理到方法学都存在一定的空缺和没有探索清楚的地方，特别是氮杂卡宾作为小分子催化的反应机理的研究和发展手性氮杂卡宾催化剂立体选择性的构建手性氨基硼酸研究方面，而该领域研究将直接推动该类化合物库构建和合成方法多样性的发展，从而对新药的研发具有极其重要的作用。
发明内容
本发明的目的是在前次申请专利（申请号：201210194758.4）的基础上，继续公开一种多样性的硼酸衍生物及其制备方法和应用，以克服现有技术存在的上述缺陷，满足相关领域发展的需要。
本发明所述的多样性的硼酸衍生物，为具有式（Ⅰ）所示结构的化合物：
其中：
R1和R2联合为儿茶酚酯、频哪醇酯、二甲氨基酯或(1S,2S,3R,5S)-(＋)-2,3-蒎烷二醇(Pinanediol)酯；优选为儿茶酚酯。
R3选自氢、1-12个碳的直链烷烃基、或3-12个碳的环烷烃基、含3-12个碳的支链烷烃基、含2-6个碳的烯烃基、含2-6个碳的炔烃、芳环基、芳杂环基、取代的含1-12个碳的直链烷烃基、或取代的3-12个碳的环烷烃基、取代的含1-12个碳的支链烷烃基、取代的含2-6个碳的烯烃基、取代的含2-6个碳的炔烃、取代的芳环基或取代的芳杂环基；
优选的，R3为氢或1-12个碳的直链烷烃基、含3-12个碳的支链烷烃基、硅烷基或取代硅烷基、苯基或取代苯基或含氮的芳杂环基。
R5为氢、3-8个碳的饱和或不饱和环烃基、含氮或氧的2-8个碳的环状烃基、含1-12个碳的直链或支链烷烃基、含2-6个碳的烯烃基、含2-6个碳的炔烃基、芳环基、芳杂环基或卤素、胺基或取代胺基；
优选的，R5为氢、1-12个碳的直链烷烃基、3-12个碳环烷烃基、含3-12个碳的支链烷烃基，或羟基、巯基、卤素取代的含1-12个碳原子的直链烷烃基、3-12个碳环烷烃基或含3-12个碳的支链烷烃基，或胺基，或苯基、取代苯基、含氮的芳杂环基取代的胺基，或者带保护基的胺基。
更优选的，R3为氢、甲基、乙基、丙基、异丙基、丁基、苯基、吡啶基、嘧啶基、四氢吡啶基；
所述的R5为氢、甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基、叔丁基、羟甲基、羟乙基、羟丙基、苯甲基、环丙基、环丁基、环戊基、环己基、苯基、氟苯基、氯苯基、吡啶基、三甲基硅烷基、甲胺基、乙胺基、Boc（叔丁氧羰基）保护的甲胺基或乙胺基、Ts（对甲苯磺酰基）保护的甲胺基或乙胺基、吲哚酮基、吲哚酮甲基、异丙基甲胺基、氟甲胺基、氟乙胺基、苯基甲胺基、对甲基苯甲胺基、对氟苯甲胺基、吡啶基甲胺基。
更优选的，所述的多样性的硼酸衍生物为：
本发明式（Ⅰ）化合物的制备方法，包括如下步骤：
在氮杂卡宾前体和碱催化下，将如通式（I’）所示的炔类化合物和二硼烷试剂在质子性溶剂中进行搅拌反应，反应温度为室温至回流温度，反应时间为1～48小时（优选为24-48小时），然后从反应产物中收集式（Ⅰ）化合物；
向反应后的混合物中加入乙酸乙酯稀释，并洗涤有机层；再用乙酸乙酯萃取水层，合并有机层并干燥过滤，减压浓缩；产品以硅胶或者用水失活的硅胶进行层析纯化。
R1、R2、R3和R5的定义同上；
所述的碱选自叔丁醇钠、碳酸钠、碳酸钾、三乙胺、1,5-二氮双环[5,4,0]十一烯-5、氟化铯、碳酸铯或氢化钠；
所述质子性溶剂选甲醇、乙醇、异丙醇、特戊醇、二氟乙醇、三氟乙醇、二氟甲醇、三氟甲醇、甲硫醇、乙硫醇、异丙硫醇、水及其混合溶剂等；
所述氮杂卡宾前体为具有如下化学结构的化合物：
其中：R6代表未取代及取代的1-6个碳的烷基、取代的1-6个碳的烷氧基、卤素、硝基、氨基、取代或并环的苯、芳环或芳杂环等；优选的为氢、3-氟、3-硝基、3-甲基、3-甲氧基或苯并；M，Q为氮或碳；R7代表1-8个碳烷基、1-8个的碳烯烃基、1-8个碳的炔烃基或芳基；X-代表氟、氯、溴或碘离子；
Ar1代表苯基、取代苯基或芳杂环基，取代苯基的取代基为甲基、氟、甲氧基，氰基或硝基；芳杂环基为吡啶基、6-甲基吡啶基、萘基、吡嗪基、吡咯基、噻吩基或嘧啶基；
其中，优选的氮杂卡宾前体为：
所述氮杂卡宾前体的制备方法，可参照以下专利（专利名称：多样性的芳基并咪唑类季铵盐及其制备方法和应用，申请号：201210195065.7）。
其中，代表性的炔类化合物I’的化学结构为：
所述二硼烷试剂（硼酸酯）为具有如式B所示结构的化合物：
其中：R1、R2的定义同上所述。
所述二硼烷试剂可商品化采购。
优选的，所述二硼烷试剂选自儿茶酚酯、频哪醇酯、二甲氨基酯、(1S,2S,3R,5S)-(＋)-2,3-蒎烷二醇（Pinanediol）酯；具体结构如下所示：
各个组分的摩尔比如下：
化合物I’∶二硼烷试剂：氮杂卡宾配体：碱＝1∶1～3∶0.05～0.2∶0.05～0.2；
本发明的多样性的硼酸，可以用于制备治疗肿瘤或糖尿病的药物，也可以作为中间体制备各种具有重要治疗作用的药物（肿瘤，二型糖尿病，丙肝，病毒等）。
本发明有益效果是：所述的多样性的硼酸衍生物，其中通过本发明制备所涉及的许多化合物是目前其他合成方法无法制备的，为新药研究提供了丰富的该类型化合物库；可以提高收率和立体选择性，可以降低该类药物的制备成本和简化合成路线，具有良好的经济效益。
具体实施方式
通法1：
将0.2mmol卡宾氮杂前体即配体L-08’（0.1eq.），0.2mmol碳酸铯（0.1eq.），炔类化合物2mol（1eq.），2mmol硼酸酯（1eq.）和溶剂甲醇（20ml），加入反应瓶中，反应液浅黄色，在室温至回流下搅拌24-48hr；用TLC监测反应进程。反应结束后加入乙酸乙酯EA（30ml）稀释，并用K2CO3洗涤有机层。之后用EA（2×30ml）萃取水层。合并有机层用Na2SO4干燥，过滤，减压浓缩。产品通过硅胶或用水失活的硅胶进行柱层析分离，展开剂使用石油醚/乙酸乙酯或氯仿/甲醇体系。
实施例1
加入204mg（2mmol）的炔类Compound35’，采用通用方法1反应，反应24小时。反应混合物通过用水失活过的硅胶经行柱层析纯化，展开剂为石油醚/乙酸乙酯或氯仿/甲醇体系。所得产物为性状在室温条件下为淡黄色油状物409mg(yield89%);1HNMR(400MHz,CDCl3,δ):7.52(m,2H),7.43(d,J=18.4Hz,1H),7.34(m,3H),6.21(d,J=18.4Hz,1H),1.34(s,12H);13CNMR(100MHz,CDCl3,δ):149.5,137.5,128.9,128.6,127.1,83.4,24.8;MS(ESI-TOF)m/z:231.2[M+H]+。
实施例2
加入240mg（2mmol）的炔类Compound42’，采用通用方法1反应，反应24小时。反应混合物通过用水失活过的硅胶经行柱层析纯化，展开剂为石油醚/乙酸乙酯或氯仿/甲醇体系。所得产物为性状在室温条件下为白色固体436mg(yield88%);mp63.9-65.4℃;1HNMR(400MHz,CDCl3,δ):7.48(m,2H),7.38(d,J=18.4Hz,1H),7.05(t,J=8.8Hz,2H),6.10(d,J=18.4Hz,1H),1.34(s,12H);13CNMR(100MHz,CDCl3,δ):163.2,148.2,133.7,128.7,128.7,115.7,115.4,83.4,24.8;19FNMR(376MHz,CDCl3,δ):-112.4;MS(ESI-TOF)m/z:249.2[M+H]+;HRMS(ESI-TOF)m/z:calcdforC14H19BFO2[M+H]+249.1457,Found249.1455.
实施例3
加入164mg（2mmol）的炔类Compound36’，采用通用方法1反应，反应24小时。反应混合物通过用水失活过的硅胶经行柱层析纯化，展开剂为石油醚/乙酸乙酯体系。所得产物为性状在室温条件下为淡黄色油状物361mg(yield86%);1HNMR(400MHz,DMSO-d6,δ):6.05(m,1H),5.30(m,1H),2.11(m,2H),1.35(m,2H),1.25(m,2H),1.18(s,12H),0.88(m,3H);13CNMR(100MHz,DMSO-d6,δ):154.7,83.1,35.3,30.3,25.1,22.2,14.2;MS(ESI-TOF)m/z:211.2[M+H]+。
实施例4
加入112mg（2mmol）的炔类Compound36-0’，采用通用方法1反应，反应24小时。反应混合物通过用水失活过的硅胶经行柱层析纯化，展开剂为石油醚/乙酸乙酯体系。所得产物为性状在室温条件下为淡黄色油状物313mg(yield85%);1HNMR(400MHz,CDCl3,δ):6.76(dd,J1=18.4Hz,J2=4Hz,1H),5.73(d,J=18.4Hz,1H),4.26(d,J=2.4Hz,2H),1.62(s,1H),1.30(s,12H);13CNMR(100MHz,CDCl3,δ):151.7,83.3,64.6,24.8;MS(ESI-TOF)m/z:185.1[M+H]+;HRMS(ESI-TOF)m/z:calcdforC9H18BO3[M+H]+185.1344,Found185.1348.
实施例5
加入140mg（2mmol）的炔类Compound36-1’，采用通用方法1反应，反应24小时。反应混合物通过用水失活过的硅胶经行柱层析纯化，展开剂为石油醚/乙酸乙酯体系。所得产物为性状在室温条件下为淡黄色油状物360mg(yield91%);1HNMR(400MHz,CDCl3,δ):6.60(dt,J1=18Hz,J2=6.4Hz,1H),5.54(d,J=18Hz,1H),3.71(t,J=6.4Hz,2H),2.42(m,2H),1.88(s,1H),1.26(s,12H);13CNMR(100MHz,CDCl3,δ):150.1,121.9,83.2,61.2,39.1,24.8;MS(ESI-TOF)m/z:199.2[M+H]+;HRMS(ESI-TOF)m/z:calcdforC10H20BO3[M+H]+199.1505,Found199.1500.
实施例6
加入310mg（2mmol）的炔类Compound36-3’，采用通用方法1反应，反应24小时。反应混合物通过用水失活过的硅胶经行柱层析纯化，展开剂为石油醚/乙酸乙酯体系。所得产物为性状在室温条件下为白色固体407mg(yield72%);mp61.6-62.8℃;1HNMR(400MHz,CDCl3,δ):6.59(dt,J1=18Hz,J2=4Hz,1H),5.59(dt,J1=18Hz,J2=6Hz,1H),4.67(s,1H),3.85(m,2H),1.45(s,9H),1.27(s,12H);13CNMR(100MHz,CDCl3,δ):155.7,149.4,118.3,83.3,79.4,44.0,28.4,24.8;MS(ESI-TOF)m/z:284.2[M+H]+;HRMS(ESI-TOF)m/z:calcdforC14H27BNO4[M+H]+284.2024,Found284.2028.
实施例7
加入132mg（2mmol）的炔类Compound37’，采用通用方法1反应，反应24小时。反应混合物通过用水失活过的硅胶经行柱层析纯化，展开剂为石油醚/乙酸乙酯体系。所得产物为性状在室温条件下为无色油状物334mg(yield86%);1HNMR(400MHz,CDCl3,δ):6.09(dd,J1=18Hz,J2=4Hz,1H),5.50(d,J1=18Hz,1H),1.53(m,1H),1.26(s,12H),0.81(m,2H),0.54(m,2H);13CNMR(100MHz,CDCl3,δ):158.5,115.3,82.9,24.7,17.0,7.9;MS(ESI-TOF)m/z:195.2[M+H]+;HRMS(ESI-TOF)m/z:calcdforC11H20BO2[M+H]+195.1551,Found195.1557.
实施例8
加入196mg（2mmol）的炔类Compound39’，采用通用方法1反应反应24小时。反应混合物通过用水失活过的硅胶经行柱层析纯化，展开剂为石油醚/乙酸乙酯体系。所得产物为性状在室温条件下为无色油状物340mg(yield75%);1HNMR(400MHz,CDCl3,δ):7.14(d,J=22Hz,1H),6.26(d,J=22Hz,1H),1.30(s,12H),0.1(s,9H);13CNMR(100MHz,CDCl3,δ):157.9,83.4,24.8,1.9;MS(ESI-TOF)m/z:227.2[M+H]+;HRMS(ESI-TOF)m/z:calcdforC11H24BO2Si[M+H]+227.1633,Found227.1638.
实施例9
加入260mg（2mmol）的炔类Compound40’，采用通用方法1反应，反应24小时。反应混合物通过用水失活过的硅胶经行柱层析纯化，展开剂为石油醚/乙酸乙酯体系。所得产物为性状在室温条件下为无色油状物443mg(yield84%);1HNMR(400MHz,CDCl3,δ):7.36(m,4H),7.28(m,2H),2.46(q,J=7.6Hz,2H),1.36(s,12H),1.16(t,J=7.6Hz,3H);13CNMR(100MHz,CDCl3,δ):141.4,137.9,129.0,128.1,127.1,83.4,24.8,22.7,14.7;MS(ESI-TOF)m/z:259.2[M+H]+;HRMS(ESI-TOF)m/z:calcdforC16H24BO2Si[M+H]+259.1864,Found259.1868.
实施例10
（1）取实施例1～9的化合物进行DPIV抑制检测，检测方法为：将样品溶解于0.01M盐酸溶液中（pH=2），配制为浓度1mg/10μl的溶液。再将样品与990μlpH=8的缓冲液中（含0.1mol/L羟乙基哌嗪乙硫磺酸HEPES和0.14mol/LnaCl），混合液室温下放置过夜。20μl浓度2.5μmol/L二肽基肽酶IV（DPIV）溶液用40mlpH=8的缓冲液（同上）稀释。底物为浓度0.1mg/ml的L-丙氨酰-L-脯氨酸-对硝基苯胺。底物和酶置于96孔板，并加入样品后在室温下摇床内孵育5分钟，再静置5分钟，410nm光检测，与空白组对照。
（2）取实施例1～9的化合物，用96孔板法进行FAP抑制的检测。
结果如表1。
表1
| 实施例化合物 | IC50(μM)DPIV（pH=8.0） | FAP IC50(μM) |
| 1 | 39 | 0.30 |
| 2 | 44 | 0.51 |
| 3 | 59 | 0.34 |
| 4 | 34 | 0.45 |
| 5 | 59 | 0.47 |
| 6 | 78 | 0.72 |
| 7 | 86 | 0.74 |
| 8 | 67 | 1.08 |
| 9 | 92 | 0.54 |
Claims (2)
1.硼酸衍生物在制备治疗肿瘤或糖尿病的药物方面的应用，其特征在于，所述硼酸衍生物结构式如式(I)所示：
其中，R1和R2联合为频哪醇酯；
R3为氢、甲基、乙基、丙基；
所述的R5为氢、甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基、叔丁基、羟甲基、羟乙基、羟丙基、环丙基、环丁基、苯基、氟苯基、氯苯基、三甲基硅烷基、Boc保护的甲氨基或乙氨基。
2.硼酸衍生物的制备方法，其特征在于，所述的硼酸衍生物结构式如式(I)所示：
其中，R1和R2联合为频哪醇酯；
R3为氢、甲基、乙基、丙基；
所述的R5为氢、甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基、叔丁基、羟甲基、羟乙基、羟丙基、环丙基、环丁基、苯基、氟苯基、氯苯基、三甲基硅烷基、Boc保护的甲氨基或乙氨基；
制备方法包括如下步骤：
在氮杂卡宾前体和碱催化下，将如通式(I’)所示的炔类化合物和二硼烷试剂在质子性溶剂中进行反应，然后从反应产物中收集式(Ⅰ)化合物；反应通式如下：
所述的炔类化合物、二硼烷试剂、氮杂卡宾前体和碱的用量比为1：1～3：0.05～0.2：0.05～0.2；
所述质子性溶剂为甲醇或乙醇；所述的碱为碳酸铯、碳酸钾或碳酸钠；所述的氮杂卡宾前体选自以下化合物：
反应温度为15℃～回流温度，反应时间为1～48小时。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310293713.7A CN103408573B (zh) | 2013-07-12 | 2013-07-12 | 硼酸衍生物及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310293713.7A CN103408573B (zh) | 2013-07-12 | 2013-07-12 | 硼酸衍生物及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103408573A CN103408573A (zh) | 2013-11-27 |
| CN103408573B true CN103408573B (zh) | 2015-12-23 |
Family
ID=49601629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310293713.7A Expired - Fee Related CN103408573B (zh) | 2013-07-12 | 2013-07-12 | 硼酸衍生物及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103408573B (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109265475B (zh) * | 2018-10-18 | 2020-08-04 | 清华大学 | 一种多取代芳基乙烯硼酸频哪醇酯衍生物的制备方法 |
| CN109776293B (zh) * | 2019-01-25 | 2022-04-05 | 温州大学 | 一种以炔酮制备1,3-二酮类化合物的方法 |
| CN111689993B (zh) * | 2019-03-11 | 2023-04-14 | 凯特立斯（深圳）科技有限公司 | 一种新的含硼类佐米药物关键中间体手性α-氨基硼酸酯的制备方法 |
| WO2021142281A1 (en) * | 2020-01-08 | 2021-07-15 | Rutgers, The State University Of New Jersey | Ligands for transition metal catalysts |
| CN113563372B (zh) * | 2021-08-31 | 2023-12-12 | 温州大学新材料与产业技术研究院 | 一种烯基硼酸酯的合成方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101273018A (zh) * | 2005-09-26 | 2008-09-24 | 惠氏公司 | 用于β分泌酶（BACE）抑制剂的氨基-5-[4-(二氟甲氧基)苯基]-5-苯基咪唑酮化合物 |
| CN102124007A (zh) * | 2008-06-12 | 2011-07-13 | 赛诺菲-安万特 | 氮杂咔啉衍生物、其制备方法和其作为激酶抑制剂的治疗用途 |
| CN102421777A (zh) * | 2009-05-12 | 2012-04-18 | 霍夫曼-拉罗奇有限公司 | 作为hsl抑制剂的氮杂环螺衍生物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006223199A1 (en) * | 2005-03-10 | 2006-09-21 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives for treatment of hyperproliferative disorders |
| TW200831091A (en) * | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
-
2013
- 2013-07-12 CN CN201310293713.7A patent/CN103408573B/zh not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101273018A (zh) * | 2005-09-26 | 2008-09-24 | 惠氏公司 | 用于β分泌酶（BACE）抑制剂的氨基-5-[4-(二氟甲氧基)苯基]-5-苯基咪唑酮化合物 |
| CN102124007A (zh) * | 2008-06-12 | 2011-07-13 | 赛诺菲-安万特 | 氮杂咔啉衍生物、其制备方法和其作为激酶抑制剂的治疗用途 |
| CN102421777A (zh) * | 2009-05-12 | 2012-04-18 | 霍夫曼-拉罗奇有限公司 | 作为hsl抑制剂的氮杂环螺衍生物 |
Non-Patent Citations (12)
| Title |
|---|
| "2-Pyrones possessing antimicrobial and cytotoxic activities";IanJ.S.Fairlamb等;《Bioorganic & Medicinal Chemistry》;20040619;第12卷;第4289页表3 * |
| "A CONVENIENT HIGHLY STEREOSELECTIVE SYNTHESIS OF CYCLOPROPYLBORONATES";Pierre Fontani等;《Tetrahedron Letters》;19891231;第30卷(第36期);第4816页方案2和表格第8列 * |
| "An efficient synthesis of 2-(1-(E)-alkenyl)phenylphosphonates via Suzuki reaction of aryl nonaflates with (E)-1-alkenylboronates";Ai-Yun Peng等;《Journal of Fluorine Chemistry》;20130328;第151卷;第59页表1 * |
| "Basic CuCO3/ligand as a new catalyst for’on water’ borylation of Michael acceptors, alkenes and alkynes: application to the efficient asymmetric synthesis ofb-alcohol type sitagliptin side chain";Gaj Stavber等;《Appl. Organometal. Chem》;20130226;第27卷(第3期);第159－165页 * |
| "Straight forward Iron-Catalyzed Synthesis of Vinylboronates by the Hydroboration of Alkynes";Michael Haberberger等;《Chem. Asian J.》;20121112;第8卷(第1期);第51－52页表4 * |
| "Synthesis of the marine sponge alkaloid oroidin and its analogues via Suzuki cross-coupling reactions";Fabienne Berre´e等;《Tetrahedron Letters》;20020708;第43卷;第4935页方案1化合物2 * |
| "Synthesis of Z (Pinacolato)allylboron and Z (Pinacolato)alkenylboron Compounds through Stereoselective Catalytic Cross-Metathesis";Elizabeth T. Kiesewetter等;《J. Am. Chem. Soc.》;20130415;第135卷;第6027页表2、第6028页方案3和方案4 * |
| Aminoboronic Esters Using Benzimidazole-Based Precursors.《J.Org.Chem.》.2013,第78卷第3405-3409页. * |
| Copper-Catalyzed Asymmetric Synthesis of α‑ * |
| Efficient C-B Bond Formation Promoted by N-Heterocyclic Carbenes:Synthesis of Tertiary and Quaternary B-Substituted Carbons through Metal-Free Catalytic Boron Conjugate Additions to Cyclic and Acyclic α，β-UnsaturatedCarbonyls;Kang-sang Lee;《J.AM.CHEM.SOC》;20090511;第131卷;第7253–7255页 * |
| Highly Selective Methods for Synthesis of Internal (α-)Vinylboronates through Efficient NHC-Cu-Catalyzed Hydroboration of Terminal Alkynes. Utility in Chemical Synthesis and Mechanistic Basis for Selectivity;Hwanjong Jang等;《J. Am. Chem. Soc.》;20110428;第133卷;第7859–7871页 * |
| Kun Wen等.Improving Carbene− * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103408573A (zh) | 2013-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Homocoupling reaction of terminal alkynes catalyzed by a reusable cationic 2, 2′-bipyridyl palladium (II)/CuI system in water | |
| CN103408573B (zh) | 硼酸衍生物及其制备方法和应用 | |
| JP7010822B2 (ja) | キラルなホスホルアミドイミデートおよびその誘導体 | |
| US9096626B2 (en) | Monophosphorus ligands and their use in cross-coupling reactions | |
| EP2044095B1 (en) | New ruthenium complexes as catalysts for metathesis reactions | |
| CN104592236A (zh) | 不对称[3+2]环加成合成手性杂环核苷类似物的方法 | |
| CN103408572B (zh) | 手性氨基硼酸衍生物及其制备方法和应用 | |
| CN103483363B (zh) | 多样性的手性氨基硼酸及其制备方法和应用 | |
| Barta et al. | A New Class of 3′‐Sulfonyl BINAPHOS Ligands: Modulation of Activity and Selectivity in Asymmetric Palladium‐Catalysed Hydrophosphorylation of Styrene | |
| Reddy et al. | Di-n-butyl ammonium chlorosulfonate ionic liquids as an efficient and recyclable catalyst for the synthesis of 1, 4-dihydrobenzo [4, 5] imidazo [1, 2-a] pyrimidine-3-carboxylates under solvent-free ultrasound irradiation | |
| CN100482644C (zh) | 一种手性双烯配体、合成方法及其在不对称反应中的应用 | |
| Gavrilov et al. | (S)‐6‐Bromo‐BINOL‐based phosphoramidite ligand with C1 symmetry for enantioselective hydrogenation and allylic substitution | |
| WO2012137460A1 (ja) | 新規ルテニウム錯体及びこれを触媒とする光学活性アルコール化合物の製造方法 | |
| CN111468183A (zh) | 多氟代三芳基手性螺环磷酸催化剂及其制备方法、用途 | |
| Li et al. | Synthesis of new chiral N-heterocyclic carbenes from naturally occurring podophyllotoxin and their application to asymmetric allylic alkylation | |
| Marques et al. | Expeditious and novel synthesis of α-hydroxyesters via rhodium–NHC catalyzed arylation of ethyl glyoxalate | |
| CN105418663B (zh) | 一种手性硼酸衍生物及其制备方法和应用 | |
| CN113045530B (zh) | 一种钌催化制备萘并吡喃类化合物的方法 | |
| CN110437277B (zh) | 一种磷酸烯基酯类化合物的合成方法 | |
| CN104744514A (zh) | 一种手性磷烯配体、合成方法及其在不对称反应中的应用 | |
| EP1935896A1 (en) | Novel optically active biaryl phosphorus compound and production process thereof | |
| CN110627831A (zh) | 二联芳缩醛膦、它们的制备方法及在偶联反应中的用途 | |
| Kubelka et al. | A general regioselective approach to 2, 4-disubstituted pyrimidin-5-yl C-2-deoxyribonucleosides | |
| Anderson et al. | Enantioselective functionalisation of the C-2′ position of 1, 2, 3, 4, 5-pentamethylazaferrocene via sparteine mediated lithiation: potential new ligands for asymmetric catalysis | |
| CN105879905B (zh) | 一种多官能团手性膦催化剂、制备方法及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151223 |